Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY AI Verdict: PROCEED
Price: $60.75 Analyst target: $69.71 Upside: 14.75%
TGTX is in a strong uptrend (close $54.79 vs SMA50 $41.64 and SMA200 $28.03, ADX 37.5). The probable catalyst is positive Azer-cel progressive MS Phase 1 data and BRIUMVI strength, which let it hold up during a broader biotech selloff. Fundamentals are solid (revenue +70% YoY, 55% profit margin, P/E 19.7, target $69.71), and news is bullish (18 of 25 articles bullish). Momentum is neutral-to-healthy (RSI 56, stochastic 66), not overbought.
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.